Anbio Biotechnology Class A Ordinary Shares

NASDAQ:NNNN

Medical - Instruments & Supplies

Healthcare
$3.60 +2.30%

+$0.37 today

Market cap
$158.01M
Beta
4.34
P/E (TTM)
99.1
EPS (TTM)
$0.16
52W Low $10.50High $55.65

Volume 0.09M

Average 0.03M

NNNN Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Anbio Biotechnology Class A Ordinary SharesNASDAQ: NNNN

Accounts Payables · Q4 FY2024 · quarter ended Dec 2024

Accounts payables turns positive

Q4 FY2024 accounts payables was $1.24M, compared with -$520.15K a year earlier. Over 3 fiscal years it compounded at +50.0% a year.

Context

  • Accounts payables amounted to 16.7% of revenue in FY2025, up 6.9 pp from a year earlier.
  • Accounts payables increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2024
$1.24M— QoQ
Last fiscal yearDec 2025
-$1.63M-303.6% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+338.5%——
1 year-303.6%——
3-year CAGR+50.0%——
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
(1.63M) USD
Year-over-year change
-303.6%

Accounts Payables vs competitors

How NNNN compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -303.6% is the lowest of 9, against a peer median of +130.5%.
  • Accounts payables amounts to 16.7% of revenue for NNNN, versus a peer median of 0.7%.
NNNN Competitors
Accounts Payables for NNNN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CYHCommunity Health Systems, Inc.LTM Mar 2026$267M USD-205.5%-38.9%1.2%
ANGOAngioDynamics, Inc.LTM Feb 2026$10.94M USD+42.4%—3.5%
CLPTClearPoint Neuro, Inc.LTM Mar 2026$5.77M USD+897.9%—14.2%
AVNSAvanos Medical, Inc.LTM Mar 2026$4.9M USD+151.0%-74.3%0.7%
GOSSGossamer Bio, Inc.LTM Mar 2026$4.35M USD+1213.0%+14.9%7.8%
CMPSCOMPASS Pathways plcLTM Mar 2026$1.81M USD+305.3%-6.6%—
NNNNAnbio Biotechnology Class A Ordinary SharesFY2025$1.63M USD-303.6%+50.0%16.7%
TALKTalkspace, Inc.LTM Mar 2026$1.13M USD-76.1%—0.5%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$532K USD+110.0%+0.6%0.2%
KALVKalVista Pharmaceuticals, Inc.LTM Dec 2025$459K USD——0.4%
SNDLSNDL Inc.LTM Mar 2026CA$0 CAD——0.0%
Peer median (excluding NNNN) —+130.5%-6.6%0.7%

Competitors are the stored peer set for NNNN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income2.54M10.01M2.25M2.37M6.4M
Depreciation & Amortization06.25K12.06K00
Deferred Income Tax00000
Stock-Based Compensation00000
Change in Working Capital1.65M(5.53M)(1.2M)44.65K(13.21M)
Accounts Receivables(717.5K)717.5K(1.88M)820.17K(2.59M)
Inventory0(353.87K)353.87K00
Accounts Payables1.89M(481.82K)(580.89K)798.1K(1.63M)
Other Working Capital473.15K(5.41M)907.97K(1.57M)(8.99M)
Other Non-Cash Items1(40.87K)(163.39K)(337.1K)68K
Operating Cash Flow4.18M4.45M898.37K2.08M(6.74M)
Capital Expenditures0(3)000
Acquisitions (Net)00000
Purchases of Investments0(16.09M)(18.54M)(35.47M)(19.42M)
Sales of Investments014.56M20.27M35.8M15.22M
Other Investing Activities00000
Investing Cash Flow0(1.53M)1.73M337.1K(4.2M)
Debt Repayment00000
Common Stock Issued00007.23M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities00(42.84K)(344.61K)(282.55K)
Financing Cash Flow00(42.84K)(344.61K)6.95M
Effect of Forex Changes00000
Net Change in Cash4.18M2.92M2.59M2.07M(3.99M)
Free Cash Flow4.18M4.45M898.37K2.08M(6.74M)

Anbio Biotechnology Class A Ordinary Shares

NASDAQ:NNNN

Intrinsic Alpha fair value

Locked

Current Price

$3.60

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.